OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
February 15, 2021
Nanoform and Herantis have signed a biologics proof of concept agreement for formulation proof of concept projects aimed at improving nasal drug delivery to the brain.
February 04, 2021
The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.
February 03, 2021
Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.
February 02, 2021
Open communication and transparency coupled with technical expertise foster strong long-term manufacturing partnerships.
January 15, 2021
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
January 04, 2021
Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.
November 03, 2020
The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.
October 03, 2020
The manufacture of gene therapy vectors is shifting to more modern technologies.
October 02, 2020
Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.
October 01, 2020
The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.